Inactive Instrument

curasan AG

CURK

DE000A2YPGM4

Curasan AG announced that it has received €1 million in funding

December 18, 2016

Curasan AG (XTRA:CUR) announced a private placement of 1,037,964 common shares at a price of €0.963425 per share for gross proceeds of around €1,000,000 on December 19, 2016.

Latest news about curasan AG

Curasan AG and Xlife Sciences AG Cooperate in the Field of Regenerative Medicine	21-06-16	CI
PBC Biomed Ltd Collaborates with curasan AG on Musculoskeletal Regeneration	21-06-08	CI
Curasan AG Appoints Dirk Dembski as New CEO	21-01-19	CI
Curasan AG Provides Revenue Guidance for the Financial Year 2019	20-05-25	CI
Curasan AG Announces CEO Changes	20-03-16	CI
Curasan AG Announces Consolidated Earnings Results for the Nine Months of 2019	19-11-21	CI
Curasan Launches Product for the Treatment of the Spinal Facet Syndrome	19-10-01	CI
Curasan AG Announces Executive Changes	19-09-12	CI
Curasan AG Reports Earnings Results for the Six Months of 2019; Provides Earnings Guidance for the Year 2019	19-08-22	CI
Tomas Kahn to Resign as Member of the Supervisory Board of curasan AG, Effective 31 August 2019	19-07-22	CI
Curasan AG announced that it expects to receive €2.938427 million in funding	19-07-21	CI
Curasan AG acquired Jeder GmbH. Dental Technology.	19-07-03	CI
Curasan AG Reports Earnings Results for the First Quarter of 2019; Provides Earnings Guidance for the Full Year of Fiscal 2019	19-05-23	CI
Curasan AG Reports Earnings Results for the Year 2018; Provides Sales Guidance for the Year 2019	19-05-13	CI
Curasan AG Announces Change of Supervisory Board	19-01-30	CI
Curasan AG, Germany Receives Approval from Japanese Pharmaceutical and Medical Devices Agency for Osbone Distribution to the Local Market	19-01-24	CI
Curasan AG Announces Consolidated Earnings Results for the Nine Months of 2018	18-11-22	CI
Curasan AG Reports Earnings Results for the Six Months of 2018; Provides Earnings Guidance for the Year 2018	18-08-23	CI
Curasan AG announced that it expects to receive €1.197 million in funding	18-07-18	CI
Curasan AG Signs Exclusive Distribution Agreement with P.J. Dahlhausen & Co. GmbH	18-06-26	CI
Curasan AG Reports Earnings Results for the First Quarter of 2018	18-05-24	CI
Curasan AG Reports Earnings Results for 2017; Provides Earnings Guidance for the Fourth Quarter, Full Year of 2018 and for 2019	18-04-26	CI
Curasan AG Signs an Exclusive Distribution Agreement with Implantcast GmbH	17-11-30	CI
Curasan AG Announces Consolidated Earnings Results for the Nine Months of 2017	17-11-09	CI
Curasan AG Announces Earnings Results for the First Half of 2017	17-08-17	CI

curasan AG is a Germany-based developer, producer and marketer of medical products in the areas of bone and tissue regeneration. The Company focuses on dentistry products and orthopedics. In the dentistry area, the Company focuses on bone regeneration and wound healing, offering CERASORB, Osbone, stypro and foils and membranes, as well as accessories, such as fixation systems. In the orthopedics area, the Company offers CERASORB, stypro and Curavisc for bone regeneration, wound healing and osteoarthritis therapy. The CERASORB product family provides bone replacement material for bone defects. stypro is a sterile and porous sponge from biomaterial that is implantable and resorbable. Osbone is a synthetic open-cell cancellous bone graft material for filling bone defects and for augmentation of the atrophied alveolar ridge.

Sector

More about the company

curasan AG

Equities

CURK

DE000A2YPGM4

Curasan AG announced that it has received €1 million in funding

Latest news about curasan AG

Chart curasan AG

Company Profile